Call for Application for 2025 Tsinghua Amgen Scholars Program

December 11, 2024 05:33 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

BEIJING, Dec. 11, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Through the 8- or 10-weeks summer program, outstanding undergraduates from across the globe can undertake research projects under the instruction of world-class faculty, get involved in cutting-edge seminars and networking events, and take part in a symposium as representatives in their respective regions. From 2025-2027, there are (will be) 25 premier educational and research institutions across the U.S., Europe, Asia, Australia and Canada which can host the Amgen summer program. In Asia, there are 4 institutions, which are Tsinghua University, National University of Singapore, University of Tokyo and Kyoto University.

The promotional poster for the ASP
The promotional poster for the ASP

10 excellent candidates studying in Asia will be selected for the coming program in 2025, whose part of meal allowance, student apartment or on-campus hotel are covered, and stipends and transport support will be offered. Each scholar will be assigned to a faculty member as his/her mentor during the research program. In addition, the scholar will have the opportunity to participate in lab and take part in a series of academic activities with postdocs, technicians or graduate students. These valuable experiences will stimulate scholars' research interests and enhance their research ability, thus providing a stable foundation for their further study. Furthermore, we will organize other extra-curricular activities, such as networking events and culture exploration, to enable scholars to make acquaintance with new friends and learn more about Chinese culture. Our program turned out to be a meaningful and salutary one, as all scholars who participated in our program from 2019 to 2024 claimed that they benefited from it profoundly and created unforgettable memories together.

In recent years, Tsinghua University actively sought to cultivate diversified talents and facilitate international collaborations and has made significant progress in innovation-driven talent development. Tsinghua's main correspondent collaborator for the ASP is the School of Pharmaceutical Sciences (SPS), which has played an important role in the university's life sciences development and frontier biomedical research. Tsinghua University will continue to provide an excellent program upon the success of previous programs with the Amgen Foundation.

For more information, please click:
http://tsinghuaamgenscholars.com/amgenscholars.html# 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.